Scor­pi­on scores $65M as it lines up a part­ner to take EGFR pro­grams glob­al

Ax­el Hoos is fir­ing up an­oth­er cylin­der in pur­suit of Scor­pi­on Ther­a­peu­tics’ vi­sion for pre­ci­sion on­col­o­gy 2.0, and it in­volves bring­ing a Eu­ro­pean play­er to his cor­ner.

Scor­pi­on will earn $65 mil­lion in up­front and near-term mile­stones for team­ing up with French phar­ma Pierre Fab­re to co-de­vel­op and com­mer­cial­ize two of its pre­clin­i­cal pro­grams that are slat­ed for IND fil­ings over the next year. While the part­ners each take the lead on one of the pro­grams, the com­mer­cial rights will be split by ge­og­ra­phy, with Scor­pi­on keep­ing rights in the US, Cana­da and Japan while Pierre Fab­re takes charge every­where else.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER